Study on c-Met Targeted PET/CT Imaging in NSCLC
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorXilin Sun
About this trial
The investigators developed a 18F labeled small molecule, 18F-TSPF, based on c-Met TKI, as a targeted molecular imaging agent for noninvasive and repeatable detecting c-Met activation status.
Eligibility criteria
Qualifiers
Age range 18-75 years, open to both male and female participants;
Normal hepatic/renal function and cardiac function;
Expected survival of at least 12 weeks;
Good adherence to follow-up;
Disqualifiers
Severe abnormalities in liver and renal function and blood counts;
Patients planning to conceive;
Pregnant or lactating women;
Individuals unable to lie flat for thirty minutes;
Trial design
Treatments tested in this trial
- 18F-TSPF PET/CT
Treatment groups
88 Participants
are divided into 1 treatment groupSponsors and collaborators
Xilin Sun
Lead sponsor
Harbin Medical University
Sponsor institution
Henan Provincial People's Hospital
Collaborator
Source ClinicalTrials.gov